Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics.

Su X, Wang Z, Li L, Zheng M, Zheng C, Gong P, Zhao P, Ma Y, Tao Q, Cai L.

Mol Pharm. 2013 May 6;10(5):1901-9. doi: 10.1021/mp300675c. Epub 2013 Apr 25.

PMID:
23570548
2.

Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics.

Wu FL, Li RT, Yang M, Yue GF, Wang HY, Liu Q, Cui FB, Wu PY, Ding H, Yu LX, Qian XP, Liu BR.

Cancer Lett. 2015 Jul 10;363(1):7-16. doi: 10.1016/j.canlet.2015.01.006. Epub 2015 Jan 12.

PMID:
25592042
3.

Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.

Li SY, Sun R, Wang HX, Shen S, Liu Y, Du XJ, Zhu YH, Jun W.

J Control Release. 2015 May 10;205:7-14. doi: 10.1016/j.jconrel.2014.11.011. Epub 2014 Nov 15.

PMID:
25445694
4.

PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells.

Du JB, Song YF, Ye WL, Cheng Y, Cui H, Liu DZ, Liu M, Zhang BL, Zhou SY.

Anticancer Drugs. 2014 Aug;25(7):751-66. doi: 10.1097/CAD.0000000000000092.

PMID:
24590167
5.

Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.

Hu K, Zhou H, Liu Y, Liu Z, Liu J, Tang J, Li J, Zhang J, Sheng W, Zhao Y, Wu Y, Chen C.

Nanoscale. 2015 May 14;7(18):8607-18. doi: 10.1039/c5nr01084e.

PMID:
25898852
6.

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.

Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL.

BMC Cancer. 2008 May 2;8:128. doi: 10.1186/1471-2407-8-128.

7.

Single-step assembly of DOX/ICG loaded lipid--polymer nanoparticles for highly effective chemo-photothermal combination therapy.

Zheng M, Yue C, Ma Y, Gong P, Zhao P, Zheng C, Sheng Z, Zhang P, Wang Z, Cai L.

ACS Nano. 2013 Mar 26;7(3):2056-67. doi: 10.1021/nn400334y. Epub 2013 Feb 22.

PMID:
23413798
8.

A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.

Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY.

Breast Cancer Res Treat. 2010 Jan;119(2):255-69. doi: 10.1007/s10549-008-0271-3. Epub 2009 Feb 17.

PMID:
19221875
9.

Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.

Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, Chen H.

Biomaterials. 2011 Nov;32(32):8281-90. doi: 10.1016/j.biomaterials.2011.07.032. Epub 2011 Jul 31.

PMID:
21807411
10.

pH-sensitive polyketal nanoparticles for drug delivery.

Wang Y, Chang B, Yang W.

J Nanosci Nanotechnol. 2012 Nov;12(11):8266-75.

PMID:
23421205
11.

Anti-cancer activity of bromelain nanoparticles by oral administration.

Bhatnagar P, Patnaik S, Srivastava AK, Mudiam MK, Shukla Y, Panda AK, Pant AB, Kumar P, Gupta KC.

J Biomed Nanotechnol. 2014 Dec;10(12):3558-75.

PMID:
26000370
12.

Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles.

Singh M, Bhatnagar P, Srivastava AK, Kumar P, Shukla Y, Gupta KC.

J Biomed Nanotechnol. 2011 Feb;7(1):202.

PMID:
21485870
13.
14.

Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.

Lee AL, Dhillon SH, Wang Y, Pervaiz S, Fan W, Yang YY.

Mol Biosyst. 2011 May;7(5):1512-22. doi: 10.1039/c0mb00266f. Epub 2011 Feb 24.

PMID:
21350763
15.

Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study.

Tang Y, Lei T, Manchanda R, Nagesetti A, Fernandez-Fernandez A, Srinivasan S, McGoron AJ.

Pharm Res. 2010 Oct;27(10):2242-53. doi: 10.1007/s11095-010-0231-6. Epub 2010 Aug 6.

PMID:
20694526
16.

Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.

Han L, Huang R, Liu S, Huang S, Jiang C.

Mol Pharm. 2010 Dec 6;7(6):2156-65. doi: 10.1021/mp100185f. Epub 2010 Oct 14.

PMID:
20857964
17.

Smac therapeutic Peptide nanoparticles inducing apoptosis of cancer cells for combination chemotherapy with Doxorubicin.

Li M, Liu P, Gao G, Deng J, Pan Z, Wu X, Xie G, Yue C, Cho CH, Ma Y, Cai L.

ACS Appl Mater Interfaces. 2015 Apr 22;7(15):8005-12. doi: 10.1021/acsami.5b00329. Epub 2015 Apr 13.

PMID:
25815797
18.

Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy.

Tan S, Sasada T, Bershteyn A, Yang K, Ioji T, Zhang Z.

Nanomedicine (Lond). 2014 Apr;9(5):635-47. doi: 10.2217/nnm.13.67. Epub 2013 Aug 1.

PMID:
23905577
19.
20.

Carboxymethyl dextran-cyclodextrin conjugate as the carrier of doxorubicin.

Sivasubramanian M, Thambi T, Deepagan VG, Saravanakumar G, Ko H, Kang YM, Park JH.

J Nanosci Nanotechnol. 2013 Nov;13(11):7271-8.

PMID:
24245242

Supplemental Content

Support Center